Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin Combined With Zimberelizumab in HER2-overexpressed Biliary Tract Cancer
NCT05540483Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2022
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, zimberelimab in biliary tract cancer (BTC), sponsored by Jiangsu Provincial People's Hospital. Status: unknown.
02
Drugs
disitamab vedotinzimberelimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05540483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05540483.